Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. LLY Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Eli Lilly (LLY)

Market Price (9/16/2025): $747.64 | Market Cap: $671.3 Bil
Sector: Health Care | Industry: Pharmaceuticals

Eli Lilly (LLY)

Market Price (9/16/2025): $747.64
Market Cap: $671.3 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%		 Weak multi-year price returns
2Y Excs Rtn is -20%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 38x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 61x, P/EPrice/Earnings or Price/(Net Income) is 49x
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, CFO LTM is 11 Bil		  
3 Low stock price volatility
Vol 12M is 40%		  
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, CFO LTM is 11 Bil
3 Low stock price volatility
Vol 12M is 40%
4 Weak multi-year price returns
2Y Excs Rtn is -20%
5 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 38x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 61x, P/EPrice/Earnings or Price/(Net Income) is 49x

Market Valuation

 9/16/252024202320222021
Share Price CYE$747.64$767.41$575.70$357.78$266.49
Market Cap CYE ($ Bil)671.3690.5518.2322.6246.7
Total Debt ($ Bil)39.933.625.216.216.9
Total Cash ($ Bil)3.53.42.92.23.9
Enterprise Value ($ Bil)707.7724.1543.4338.8263.6
Valuation Ratios     
P/S TTM12.615.415.411.68.8
P/EBIT TTM37.851.674.546.238.6
P/E TTM48.665.7100.152.844.9
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.9-1.6-1.5-1.4-2.9
 9/16/2520242023
Share Price CYE$747.64$767.41$575.70
Market Cap CYE ($ Bil)671.3690.5518.2
Total Debt ($ Bil)39.933.625.2
Total Cash ($ Bil)3.53.42.9
Enterprise Value ($ Bil)707.7724.1543.4
Valuation Ratios   
P/S TTM12.615.415.4
P/EBIT TTM37.851.674.5
P/E TTM48.665.7100.1
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.9-1.6-1.5

Market Cap Chart

Business Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
LLY Return31%66%34%61%33%-3%517%
Peers Return3%28%19%-2%7%-11%47%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: MRK, PFE, BMY, BDX, LLY. See LLY Returns vs. Peers.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Eli Lilly Earnings Notes  
2Things To Be Wary Of When Buying Eli Lilly StockBuy or Fear 
3LLY Soars 16% In A Single Month: How Does It Compare With Others?  
4A Decade of Rewards: LLY Returns $47 Bil to Investors  
5After LLY's 12% Climb in a Week, FANG Looks Like the Stronger Long-Term PlayCounter-Intuitive Comparisons 
6Day 5 of Gains Streak for Eli Lilly Stock with 12% Return (vs. -8.6% YTD) [8/15/2025]Notification 
7Better Bet Than LLY Stock: Pay Less Than Eli Lilly To Get More From CALM, ADMA   
8Better Bet Than LLY Stock: Pay Less Than Eli Lilly To Get More From ADMA, PTCT   
9Eli Lilly vs. Merck: With Return Forecast Of 48%, Eli Lilly Is A Better BetPeer Comparison 
10LLY YTD Stock Return Of -4.7% Outperforms BDX by 21% and Underperforms GSK by -14%Return 
11ARTICLES  
12LLY Leaps 16% In One Month, Things To Be Wary Of When Buying The Stock September 9th, 2025
13LLY Soars 16% In A Single Month: How Does It Compare With Others? September 9th, 2025
14Ten-Year Tally: LLY Hands Back $47 Bil to Shareholders September 6th, 2025
15LLY Has Paid Out $47 Bil to Investors in the Past Decade September 6th, 2025
16LLY Up 5.9% in One Day: Is It Outperforming Its Rivals? August 26th, 2025
Title
0DASHBOARDS
1LLY Leaps 16% In One Month, Things To Be Wary Of When Buying The Stock
2LLY Soars 16% In A Single Month: How Does It Compare With Others?
3Ten-Year Tally: LLY Hands Back $47 Bil to Shareholders
4LLY Has Paid Out $47 Bil to Investors in the Past Decade
5LLY Up 5.9% in One Day: Is It Outperforming Its Rivals?
6ARTICLES
7Eli Lilly Earnings Notes
8Things To Be Wary Of When Buying Eli Lilly Stock
9LLY Soars 16% In A Single Month: How Does It Compare With Others?
10A Decade of Rewards: LLY Returns $47 Bil to Investors
11After LLY's 12% Climb in a Week, FANG Looks Like the Stronger Long-Term Play
12Day 5 of Gains Streak for Eli Lilly Stock with 12% Return (vs. -8.6% YTD) [8/15/2025]
13Better Bet Than LLY Stock: Pay Less Than Eli Lilly To Get More From CALM, ADMA 
14Better Bet Than LLY Stock: Pay Less Than Eli Lilly To Get More From ADMA, PTCT 
15Eli Lilly vs. Merck: With Return Forecast Of 48%, Eli Lilly Is A Better Bet
16LLY YTD Stock Return Of -4.7% Outperforms BDX by 21% and Underperforms GSK by -14%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO7309.3% 
3CHSNChanson International5551.3%-99.3%
4LNZALanzaTech Global5145.9%-85.7%
5QMMMQMMM2490.3%5505.5%
6NXTTNext Technology2167.7%1080.3%
7VTAKCatheter Precision1543.9%-70.5%
8CURXCuranex Pharmaceuticals1282.0%1282.0%
9VCIGVCI Global1278.3%-66.8%
10OCTOEightco800.6%562.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-93.3%-95.1%
2ELPWElong Power-92.4%-76.5%
3STFSStar Fashion Culture-92.1%-97.9%
4ETSElite Express-92.0%-92.0%
5NAKAKindly MD-91.7% 
6BINIBollinger Innovations-90.5%-100.0%
7FLYEFly-E-89.8%-81.2%
8JEM707 Cayman-89.8%-98.3%
9NUTRNusaTrip-86.7%-86.7%
10CUPRCuprina-84.9% 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Eli Lilly

Financials

LLYMRKPFEBMYBDXMedian
NameEli LillyMerck Pfizer Bristol-.Becton D. 
Mkt Price748.1981.0223.9746.35185.7481.02
Mkt Cap671.8203.4136.394.153.3136.3
Rev LTM53,25863,61663,83347,63621,38653,258
Op Inc LTM22,88219,82116,6637,8702,95516,663
FCF LTM-5014,72212,43813,0862,55012,438
FCF 3Y Avg-15612,8999,30412,2252,5049,304
CFO LTM10,93818,53415,18814,3103,25414,310
CFO 3Y Avg7,23016,76612,58413,4193,27812,584

Growth & Margins

LLYMRKPFEBMYBDXMedian
NameEli LillyMerck Pfizer Bristol-.Becton D. 
Rev Chg LTM36.8%1.8%13.5%4.6%7.9%7.9%
Rev Chg 3Y Avg23.4%3.7%-12.4%0.5%4.1%3.7%
Rev Chg Q37.6%-1.9%10.3%-5.6%10.4%10.3%
QoQ Delta Rev Chg LTM8.7%-0.5%2.2%-1.4%2.5%2.2%
Op Mgn LTM43.0%31.2%26.1%16.5%13.8%26.1%
Op Mgn 3Y Avg35.6%22.6%20.2%17.3%13.3%20.2%
QoQ Delta Op Mgn LTM1.8%-0.8%1.8%4.3%0.9%1.8%
CFO/Rev LTM20.5%29.1%23.8%30.0%15.2%23.8%
CFO/Rev 3Y Avg17.8%27.2%18.8%28.9%16.3%18.8%
FCF/Rev LTM-0.1%23.1%19.5%27.5%11.9%19.5%
FCF/Rev 3Y Avg0.5%20.9%13.8%26.4%12.4%13.8%

Valuation

LLYMRKPFEBMYBDXMedian
NameEli LillyMerck Pfizer Bristol-.Becton D. 
Mkt Cap671.8203.4136.394.153.3136.3
P/S12.63.22.12.02.52.5
P/EBIT37.810.010.211.621.311.6
P/E48.712.412.717.433.717.4
P/CFO61.411.09.06.616.411.0
Total Yield2.8%12.0%13.2%11.0%5.2%11.0%
Dividend Yield0.7%3.9%5.3%5.2%2.2%3.9%
FCF Yield 3Y Avg0.1%5.1%5.7%12.4%4.1%5.1%
D/E0.10.20.40.50.40.4
Net D/E0.10.10.30.40.30.3

Returns

LLYMRKPFEBMYBDXMedian
NameEli LillyMerck Pfizer Bristol-.Becton D. 
1M Rtn6.7%-2.8%-4.7%-4.3%-4.7%-4.3%
3M Rtn-7.2%1.1%-0.1%-4.7%8.5%-0.1%
6M Rtn-8.9%-12.8%-4.6%-21.9%-17.5%-12.8%
12M Rtn-18.4%-27.0%-12.4%-2.5%-19.0%-18.4%
3Y Rtn148.4%1.0%-38.6%-27.4%-23.1%-23.1%
1M Excs Rtn7.3%-3.4%-6.8%-5.3%-6.5%-5.3%
3M Excs Rtn-19.2%-9.5%-11.3%-17.5%-2.2%-11.3%
6M Excs Rtn-24.9%-29.2%-20.7%-37.9%-34.2%-29.2%
12M Excs Rtn-37.2%-45.4%-32.6%-20.5%-38.0%-37.2%
3Y Excs Rtn78.0%-63.0%-105.1%-90.3%-90.1%-90.1%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/1/20252/19/202510/30/20248/8/20244/30/20242/21/202411/2/20238/8/20234/27/20232/22/202311/1/2022
Key Financials Quarterly            
Total Revenue15,55812,72813,53311,43911,3038,7689,3539,4998,3126,9607,3026,942
Ebitda7,5044,1635,7482,2484,1153,1163,0359632,5761,9952,5552,010
Operating Income7,1265,4085,7984,5504,4182,7363,1933,5412,3381,7152,2082,038
Net Income5,6602,7594,4109702,9672,2432,190-571,7631,3451,9381,452
EPS6.303.074.911.083.292.492.43-0.061.961.492.041.61
Key Financials TTM            
Total Revenue TTM53,25849,00345,04340,86338,92335,93234,12432,07229,51627,69128,54129,240
Ebitda TTM19,66316,27415,22812,51411,2299,6898,5688,0889,1368,0818,6608,472
Operating Income TTM22,88220,17417,50214,89713,88811,80810,7879,8028,2987,7058,6538,978
Net Income TTM13,80011,10610,5908,3707,3426,1385,2404,9886,4985,6876,2456,033
Growth Rates Quarterly            
Total Revenue Growth37.6%45.2%44.7%20.4%36.0%26.0%28.1%36.8%28.1%-10.9%-8.7%2.5%
EBITDA Growth82.3%33.6%89.4%133.5%59.8%56.2%18.8%-52.1%69.3%-22.5%8.0%17.5%
Operating Income Growth61.3%97.7%81.6%28.5%89.0%59.5%44.6%73.8%34.0%-35.6%-12.8%-4.4%
Net Income Growth90.8%23.0%101.4%1790.4%68.3%66.8%13.0%-104.0%85.1%-29.3%12.3%30.8%
Margins Quarterly            
EBITDA Margin48.2%32.7%42.5%19.7%36.4%35.5%32.4%10.1%31.0%28.7%35.0%29.0%
Operating Income Margin45.8%42.5%42.8%39.8%39.1%31.2%34.1%37.3%28.1%24.6%30.2%29.4%
Net Income Margin36.4%21.7%32.6%8.5%26.3%25.6%23.4%-0.6%21.2%19.3%26.5%20.9%
Cash & Debt            
Total Cash3,5463,2213,4233,5183,3642,5862,9282,4942,8293,6692,2122,742
Total Debt39,90438,51633,64431,12028,89226,21125,22520,16818,82018,88416,23915,888
Net Debt / (Cash)36,35835,29530,22127,60125,52823,62522,29817,67415,99115,21414,02713,146
Cash Flows Quarterly            
FCF from Operations3,0871,6662,4743,7121,4661,166-3122,1906321,7311,6632,217
Cash Flows TTM            
FCF from Operations TTM10,9389,3188,8186,0324,5103,6764,2406,2156,2426,7937,5868,185
Returns to Shareholders Quarterly            
Dividends1,3471,3461,1681,1701,1721,1691,0181,0161,0181,017884882
Share Repurchases6921,2002,054446-0-0-0-0-0750-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC64.0%48.1%65.9%39.4%57.6%40.6%49.1%76.4%47.4%38.4%56.0%57.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM50.3%45.9%47.4%43.6%43.8%40.2%38.0%42.9%44.5%44.4%54.4%62.8%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Trulicity7,1327,4406,4725,0684,128
Mounjaro5,1634820  
Verzenio3,8632,4841,350913580
Taltz2,7602,4822,2131,7881,366
Jardiance2,7452,0661,4911,154944
Zyprexa1,695337430406419
Humalog1,6632,0612,4532,6262,821
Other1,1221,496370  
Cyramza9759711,0331,033925
Olumiant9238301,115639427
Humulin8521,0191,2221,2601,290
Other Oncology8301,352331  
Basaglar7287608921,1241,113
Emgality678651577363162
Baqsimi678139113  
Erbitux596566548536543
Other cardiometabolic health530497544  
Other Neuroscience506558891  
Tyvyt393293418309 
Zepbound17600  
Other Immunology1153233  
COVID-19 Antibodies02,0242,239871 
Alimta  2,0612,3302,116
Cialis  718607890
Forteo  8021,0461,405
Cymbalta   768725
Other products   1,3401,874
Trajenta   358591
Total34,12428,54228,31824,54022,320


Price Behavior

LLY Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.200.320.470.710.660.60
Up Beta-1.69-0.75-0.710.390.340.48
Down Beta-4.17-2.97-1.780.750.640.69
Up Capture126%134%121%74%67%43%
Bmk +ve Days10223571142415
Stock +ve Days13264070132416
Down Capture188%284%218%125%112%80%
Bmk -ve Days11192754106334
Stock -ve Days8162356117335

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity8,041,246
Short Interest: % Change Since 8152025-7.5%
Average Daily Volume4,250,575
Days-to-Cover Short Interest1.89
Basic Shares Quantity897,900,000
Short % of Basic Shares0.9%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/2025-14.1%-11.5%-2.4%
5/1/2025-11.7%-13.6%-17.8%
1/14/2025-6.6%-6.9%9.5%
10/30/2024-6.3%-10.8%-12.6%
8/8/20249.5%20.7%17.1%
4/30/20246.0%4.0%10.3%
2/6/2024-0.2%4.4%10.6%
11/2/20234.7%11.7%5.5%
...
SUMMARY STATS   
# Positive101215
# Negative13118
Median Positive4.0%4.9%7.2%
Median Negative-3.5%-4.6%-7.1%
Max Positive14.9%20.7%23.6%
Max Negative-14.1%-13.6%-17.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024219202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024808202410-Q 6/30/2024
3312024430202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023808202310-Q 6/30/2023
3312023427202310-Q 3/31/2023
12312022222202310-K 12/31/2022
93020221101202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021223202210-K 12/31/2021
93020211027202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Zakrowski Donald ASVP, Finance, & CAO8282025Sell734.931,000734,9302,821,881Form
1Montarce LucasEVP & CFO8152025Buy691.79715494,62710,158,695Form
2Alvarez Ralph 8142025Buy660.25758500,473500,473Form
3Van Naarden JacobEVP & Pres., Lilly Oncology8132025Buy647.361,000647,36013,311,007Form
4Ricks David APresident, Chair, and CEO8122025Buy644.771,6321,052,263352,431,488Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.